Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 113Recruiting 35Terminated 32Active not recruiting 25Unknown 18Withdrawn 7Not yet recruiting 3Enrolling by invitation 1

Sponsor Class

OTHER 5NIH 1INDUSTRY 1

Study Type

Interventional 7Observational 2

Sponsor

Cancer Type

Dermatologic 7Breast 1

Conditions

Breast Neoplasms 370Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 142Colorectal Neoplasms 139Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 123Lymphoma 115Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 89Head and Neck Neoplasms 89Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 62Hematologic Neoplasms 59Sarcoma 55Glioma 53

Interventions

trametinib 2olaparib 1glembatumumab vedotin 1durvalumab 1cediranib 1Vorinostat 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1CR011-vcMMAE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Uveal Melanoma × Clear all
NCT05482074 2024-01-19

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Dermatologic

Uveal Melanoma, Melanoma

NCT05677373 2023-08-18

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
Dermatologic

Uveal Melanoma

NCT04184518 2020-06-02

CEDUVEAL-M

Grupo Español Multidisciplinar de Melanoma

Phase 2 Withdrawn
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT03022565 2020-02-06

Vorinostat in Patients With Class 2 High Risk Uveal Melanoma

University of Miami

Phase EARLY_PHASE1 Withdrawn
Dermatologic

Uveal Melanoma

NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01328106 2017-12-12

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

GlaxoSmithKline

Phase 2 Withdrawn
Dermatologic

Uveal Melanoma, Neoplasms

NCT00621439 2013-12-02

Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye

Emory University

Phase NA Withdrawn
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡